Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 1% – Should You Sell?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) shares traded down 1% during trading on Monday . The stock traded as low as $1.8503 and last traded at $1.91. Approximately 17,664 shares changed hands during mid-day trading, an increase of 84% from the average daily volume of 9,605 shares. The stock had previously closed at $1.93.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Alaunos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Alaunos Therapeutics Price Performance

The company’s fifty day simple moving average is $2.06 and its 200-day simple moving average is $2.55. The firm has a market capitalization of $46.64 million, a PE ratio of -1.00 and a beta of -1.00.

Alaunos Therapeutics (NASDAQ:TCRT) last released its earnings results on Friday, August 14th. The company reported ($0.41) EPS for the quarter.

Hedge Funds Weigh In On Alaunos Therapeutics

An institutional investor recently raised its stake in Alaunos Therapeutics stock. Geode Capital Management LLC lifted its position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) by 25.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,736 shares of the company’s stock after acquiring an additional 3,945 shares during the period. Geode Capital Management LLC owned 0.85% of Alaunos Therapeutics worth $64,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 27.72% of the company’s stock.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.